Related Experiment Video
Updated: Jun 12, 2026

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology
Published on: March 15, 2024
Beyond A1c: Redefining Evidence and Policy to Advance Therapies in Type 1 Diabetes Care
Huajing Ni1,2, Jerry R Greenfield1,2,3, Jennifer R Snaith2
1Victor Chang Cardiac Research Institute, Darlinghurst, Sydney, Australia.
Abstract:
Innovation in technology has revolutionized modern-day type 1 diabetes (T1D) care, significantly improving glycaemic control and the patient experience. However, the outcome measures used in clinical trials, which inform policies, remain stagnant. Progress has been made in the search for adjunctive therapies beyond insulin to reduce residual cardiometabolic risk. The importance of patient-centred strategies is also increasingly recognized. The future of T1D research calls for the adaptation by regulators to accept additional endpoints beyond haemoglobin A1C (HbA1c).
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Type I Diabetes III: Clinical Manifestations
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

